Literature DB >> 19436973

[Successful therapy of discoid lupus erythematosus with efalizumab].

N Booken1, T Schumann, M Fuchslocher, S Goerdt, M Goebeler.   

Abstract

The therapy of discoid lupus erythematosus (DLE) is occasionally a therapeutic challenge. Topical treatment is often not sufficient and therapy with antimalarials [(hydroxy-) chloroquine] not always successful. We report on a 50-year-old male patient with recalcitrant chronic DLE who experienced within 12 weeks at first improvement and then almost complete remission for 11 months after off-label application of the anti-CD11a antibody efalizumab.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19436973     DOI： 10.1007/s00105-009-1767-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  10 in total

Review 1.  [Systemic treatment of cutaneous lupus erythematosus].

Authors:  Joerg Wenzel; Thomas Bieber; Manfred Uerlich; Thomas Tüting
Journal:  J Dtsch Dermatol Ges       Date:  2003-09       Impact factor: 5.584

2.  Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab.

Authors:  Timothy H Clayton; Stephanie Ogden; Mark D J Goodfield
Journal:  J Am Acad Dermatol       Date:  2006-05       Impact factor: 11.527

3.  Efalizumab-induced subacute cutaneous lupus erythematosus.

Authors:  Danette D Bentley; Julia E Graves; David I Smith; Michael P Heffernan
Journal:  J Am Acad Dermatol       Date:  2006-05       Impact factor: 11.527

4.  Drug-induced systemic lupus erythematosus and TNF-alpha blockers.

Authors:  G F Ferraccioli; R Assaloni; A Perin
Journal:  Lancet       Date:  2002-08-24       Impact factor: 79.321

5.  Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab.

Authors:  A Hamprecht; T Tüting; T Bieber; J Wenzel
Journal:  Clin Exp Dermatol       Date:  2008-01-14       Impact factor: 3.470

6.  Efalizumab-induced lupus-like syndrome.

Authors:  Hélene Durox; Agnès Sparsa; Véronique Loustaud-Ratti; Sorilla Prey; Guillaume Gondran; Petrus Manea; Elisabeth Vidal; Christophe Bedane
Journal:  Acta Derm Venereol       Date:  2008       Impact factor: 4.437

7.  Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.

Authors:  Minerva Gómez; Maira E Herz Ruelas; Oliverio Welsh; Horacio Decanini Arcaute; Jorge Ocampo-Candiani
Journal:  J Drugs Dermatol       Date:  2007-03       Impact factor: 2.114

Review 8.  [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].

Authors:  G Guhl; B Díaz-Ley; J Fernández-Herrera
Journal:  Actas Dermosifiliogr       Date:  2008 Jan-Feb

Review 9.  Efalizumab.

Authors:  Manju Chacko; Jeffrey M Weinberg
Journal:  Dermatol Ther       Date:  2007 Jul-Aug       Impact factor: 2.851

10.  Efalizumab in the treatment of discoid lupus erythematosus.

Authors:  Naila Usmani; Mark Goodfield
Journal:  Arch Dermatol       Date:  2007-07
  10 in total
  1 in total

1.  Acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus: a retrospective case-control study.

Authors:  Ajaykumar B Patel; Christopher L Hallemeier; Ivy A Petersen; Ashley W Jensen; Thomas G Osborn; Robert C Miller
Journal:  Radiat Oncol       Date:  2012-02-16       Impact factor: 3.481
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.